We describe the use of a commercially available high content cell imaging algorithm (Cellomics Arrayscan Spot Detector) to quantify biliary excretion of the fluorescent probe substrate cholyl-L-lysyl-fluorescein (CLF) from rat hepatocytes cultured in collagen/matrigel sandwich configuration and to explore inhibition of this process by a variety of test compounds. The method provided robust, reproducible data. Twenty-nine pharmaceuticals inhibited biliary CLF efflux from hepatocytes and a broad range of potencies of inhibition were observed (IC 50 values ranged between <1 and 794 mM). Thirteen drugs that inhibited CLF efflux also inhibited hepatocellular uptake of the probe substrate [ 3 H]-taurocholate. Although no clear correlation between the potencies of inhibition of the 2 processes was evident, these data highlight the need to consider possible uptake transporter inhibition when interpreting hepatocyte CLF inhibition data. It has been reported that CLF is transported by MRP2. The CLF efflux inhibition data correlated closely with published data on inhibition by the drugs of the bile salt export pump (Bsep), which suggests that the tested drugs inhibit both Bsep and Mrp2. Calculation of the ratios between the maximum human plasma concentrations of the drugs and their CLF efflux inhibition IC 50 values raised the possibility that for many, but not all, of them the in vitro effects may be functionally significant in vivo and that Mrp2 inhibition might be a drug-induced liver injury (DILI) risk factor. These data indicate that imaging hepatocyte CLF inhibition is a promising new method for quantification of biliary efflux inhibition by drugs, which could aid assessment of compound-related DILI risk.
uptake of bile salts, bilirubin, and other metabolic products (including drug metabolites) from the bloodstream. These are the sodium taurocholate co-transporting polypeptide (NTCP; SLC10A1) and several organic anion transporting polypeptides (OATPs; SLCOs) (Stieger and Meier, 1998) .
Mutations in the genes which encode hepatocyte apical efflux transporters cause a variety of rare inherited forms of human liver injury. The most severe consequence is Progressive Familial Intrahepatic Cholestasis type 2 (PFIC2), which is caused by ABCB11 gene mutations that result in loss of functional BSEP expression. PFIC2 is characterized by cholestasis soon after birth, a progressive subsequent loss of liver function and fatal liver failure unless liver transplantation is undertaken (Byrne et al., 2009; Ho et al., 2010; Strautnieks et al., 2008) . Less functionally severe ABCB11 gene mutations occur in patients with Benign Recurrent Intrahepatic Cholestasis type 2 (BRIC2), who exhibit non-progressive cholestasis (Noe et al., 2005) . Mutations in the ABCC2 gene, which encodes MRP2, result in hyperbilirubinemia and jaundice, but not degenerative liver damage, and in humans is termed Dubin-Johnson syndrome (Kartenbeck et al., 1996) .
An additional important cause of rare, but potentially severe, human liver injury is ingestion of prescription drugs. Druginduced liver injury (DILI) is caused by many hundreds of licensed pharmaceuticals, and is a leading reason for withdrawal of licensed drugs, failed registration, and compound attrition during drug discovery and clinical development. Numerous drugs which cause human DILI inhibit BSEP activity in vitro (Dawson et al., 2012; Kö ck et al., 2013; Morgan et al., 2010) and several drugs which cause DILI have been found to cause elevated total plasma bile acid levels in animals and humans, demonstrating that they inhibit hepatobiliary transporter function in vivo (Funk et al., 2001a) . It has been found that the frequency and potency of BSEP inhibition in vitro is markedly greater for many drugs which cause cholestatic, or mixed hepatocellular/cholestatic, human DILI than for drugs which do not cause DILI, or which cause hepatocellular DILI (Dawson et al., 2012; Morgan et al., 2010) . It has therefore been proposed that BSEP inhibition is an important mechanism which may initiate DILI, and that proactive evaluation of BSEP inhibition during drug discovery may aid the selection of new drugs which have reduced propensity to cause DILI.
The most commonly used approach for in vitro assessment of drug-induced BSEP inhibition involves the use of membrane vesicles from transiently transfected insect cell lines. Although such assays provide robust and quantitative data, are technically straightforward, and are well suited to medium/high throughput data generation, they exhibit no biotransformation capability and so may underestimate the potential DILI liability of drugs whose metabolites are more potent BSEP inhibitors than the parent compounds (eg, troglitazone sulfate; Funk et al., 2001a, b) . Membranes which express only BSEP are also unsuitable for detection of transporter inhibition requiring co-expression of other biliary transporters, as has been observed for estradiol-b,D-glucuronide (Huang et al., 2000) .
Therefore, it is important also to undertake studies using more complex and physiologically relevant in vitro models, which co-express multiple hepatobiliary transporter proteins, and also exhibit metabolic capability. Hepatocytes cultured in vitro in sandwich configuration (SCH) exhibit polarized expression of a variety of relevant transporter proteins, and retain significant metabolic capability (Liu et al., 1999; Sidhu et al., 1993) . However, evaluation of apical plasma membrane efflux from SCH is technically challenging and typically is undertaken using an indirect approach that requires comparison between test compound efflux from SCH culture media maintained in calcium-containing media and calcium-free media (Kö ck et al., 2013) . We describe an alternative method, which uses a commercially available high content cell imaging algorithm (Cellomics Arrayscan), to visualize directly the biliary excretion of the fluorescent probe substrate cholyl-L-lysyl-fluorescein (CLF) from SCH, and quantify the inhibition of this process by drugs which cause human cholestatic DILI.
MATERIALS AND METHODS

Materials.
[ 3 H]-taurocholate (1 mCi/ml) was obtained from Perkin Elmer Life and Analytical Sciences (Waltham, Massachusetts). CLF was synthesized as described by Mills et al. (1991) . Anti-BSEP was purchased from Kamiya Biomedical (Seattle, Washington); anti-MRP2 (M2 III-6), anti-P-glycoprotein (C219; Pgp ¼ multidrug resistance protein 1, ABCB1), and goat antimouse IgG-FITC were from Abcam (Cambridge, UK). Donkey anti-rabbit AlexaFluor 488, goat anti-mouse AlexaFluor 647, and phalloidin-AlexaFluor 568 were from Molecular Probes (Invitrogen, Paisley, UK). Phenol Red-free William's Media E (WME), bovine insulin, and dexamethasone were from Sigma (Poole, UK). Cell culture supplements were from Invitrogen. Phenol red-free Matrigel and BioCoat plates were from Becton Dickinson (Oxford, UK). All drugs (>95% purity) were from Sigma. Male Han Wistar rats were obtained from Charles River Laboratories (Margate, UK) and were housed in a temperaturecontrolled environment in a 12-h light-dark cycle, with free access to food and water. All other chemicals were from Sigma Aldrich (Poole, Dorset, UK) and cell culture supplements from Invitrogen.
Rat primary hepatocyte isolation and culture. Hepatocytes from male Han Wistar rats (200-300 g) were isolated in situ by collagenase perfusion (Seglen, 1976) . The resulting cell suspensions were mixed with equal volumes of 90% isotonic Percoll, centrifuged at 60 Â g for 10 min and re-suspended in WME supplemented with 10 U/ml penicillin, 10 lg/ml streptomycin, 10% heat inactivated fetal bovine serum (FBS), 30 nM dexamethasone, 50 lg/ml gentamycin, 10 mM HEPES, and 1 Â glutamax-I. Cell viability was determined by trypan blue exclusion and was !85%. Hepatocytes were cultured in SCH, as described by LeCluyse et al. (1994) . Initially, freshly isolated and purified hepatocytes were seeded into wells of 6-well BioCoat plates at 100 000 cells/cm 2 and were incubated in supplemented WME for 1 h at 37 C, 5% CO 2 , 95% humidity to enable their attachment.
The medium was then replaced with maintenance WME (supplemented WME minus FBS) which also contained 250 lg/ml Matrigel then were incubated for a further 24 h 37 C, 5% CO 2 , 95% humidity. The medium was then replaced once more with maintenance WME and incubation was continued under the same conditions for up to a further 4 days, with further medium changes being undertaken at daily intervals.
Immunocytochemistry. SCH were washed with Hanks-Buffered Saline Solution (HBSS) and then were fixed for 10 min in 3.7% formaldehyde at room temperature prior to visualization of Bsep or Mrp2, or for 10 min in 100% methanol at À20 C prior to visualization of P-gp. All subsequent steps were undertaken at room temperature. The fixed hepatocytes were rehydrated in blocking buffer (Tris-buffered saline, 1.1% BSA, 0.2% Triton X-100) for 30 min, then were incubated for 2 h with primary antibodies diluted in blocking buffer (BSEP 1:400, MRP2 This was because larger numbers of dead cells were observed at higher seeding densities following addition of the CLF probe substrate, which caused autofluorescence and thereby impaired the ability of the algorithm to detect and quantify CLF efflux into canalicular pockets. The compound concentrations were achieved by dilution from stock solutions prepared in DMSO. All compounds were tested up to a concentration of 1000 mM with the exception of cyclosporine A, troglitazone, erythromycin, ketoconazole, nefadozone, and flutamide, which were tested at maximum concentrations of 100 mM. Compound solubility in the final cell culture media was verified by visual inspection and these compound concentrations did not cause detectable cell cytotoxicity.
[ 3 H]-taurocholate uptake by SCH and its inhibition by test compounds.
On day 5 after their isolation and initial plating, SCH were washed twice in HBSS, incubated for 10 min at 37 C in fresh HBSS, then incubated for a further 25 min at 37 C in HBSS which contained 1 mM [ 3 H]-taurocholate and either DMSO vehicle or test compound diluted in DMSO. In all incubations the final DMSO concentration was 0.4% (v/v) and the final compound concentrations were those used in the CLF efflux inhibition studies. Subsequently, the cells were washed 4 times with cold HBSS and then were lysed using Sigma ATP releasing agent. Aliquots of the cell lysates were taken for scintillation counting. The amounts of radiolabel accumulated by the cells were normalized to their total solubilized protein contents, which were determined using a Pierce BCA kit (Northumberland, UK).
Cytotoxicity of test compounds to SCH. Following incubation of SCH with test compounds, culture media were removed by aspiration and cells were lysed using ATP cell lysate reagent. The ATP content (Sigma ATP kit) and protein content (Pierce BCA kit) of the cell lysates were determined, as were the LDH activities (Roche Diagnostics, Welwyn, UK) present in the culture media plus the cell lysates (Roche Diagnostics). For DMSO-treated SCH, ATP contents were between 12 and 20 nmol/mg protein and LDH leakage into culture media was <5% of the total activity present in cells plus culture media.
Data analysis. IC 50 values were calculated using Origin Client software.
DILI annotation of pharmaceuticals. The severities and patterns of DILI caused in humans by the 41 tested drugs were categorized using the scheme described by Gustafsson et al. (2014) . This utilized information which was extracted from the scientific literature and from US FDA approved product labels, which is summarized in Table 1 . Each drug was assigned to 1 of 3 DILI patterns (hepatocellular, cholestatic, or mixed) and to 1 of 4 DILI concern categories (severe, high concern, DILI reports, and no DILI). Drugs in the Severe DILI category (n ¼ 6) caused cases of fatal liver failure which had resulted in either withdrawal or FDA Black Box warnings. High DILI concern category drugs (n ¼ 11) caused cases of liver failure that resulted in cautionary labeling and restricted drug usage, but not Black Box warnings or drug withdrawal. Drugs with DILI reports (n ¼ 22) caused isolated and infrequent cases of DILI which resulted in cautionary labeling, but have not been reported to cause liver failure. The No DILI drugs (n ¼ 2) have not been found to cause cases of symptomatic liver injury. Data on the prescribed doses of the drugs, their extents of plasma protein binding, their maximum reported plasma concentration (C max ), and their estimated maximum unbound plasma concentrations (C max,u ) are also provided in Table 1 .
RESULTS
Polarized Expression of Plasma Membrane Transporters in SCH
Immediately after their isolation by collagenase digestion, rat hepatocytes exhibited high viability (!85%) but had lost their characteristic polygonal appearance and polarized expression of basolateral and apical plasma membrane transporters. Cell viability was maintained in SCH and these cells regained their plasma membrane polarity progressively over several days. Canalicular structures between adjacent cells were evident by light microscopy from day 2 onwards (24 h after cell plating; Literature citations are provided in Gustafsson et al. (2014) , with the exception of Rifamycin SV (data from Dawson et al., 2012; Stricker, 1992) and famotidine (data from Dawson et al., 2012; FDA DailyMed, 2013) .
BARBER ET AL. | 51 either within SCH or on apical plasma membrane domains between adjacent cells which co-expressed actin (yellow fluorescence, due to co-localization of green anti-BSEP staining and red phalloidin-AlexaFluor 568 staining of actin, Fig. 1C ). In contrast, Bsep was localized almost exclusively to plasma membrane domains between adjacent SCH on day 5 (Fig. 1D ), as were the apical transporters Mrp2 and P-gp (Figs. 1E  and 1F ). Quantification by RT-PCR revealed that the levels of expression of mRNA encoding Bsep and Mrp2 in SCH on day 5 were similar to those observed in freshly isolated hepatocytes, or in whole rat liver (Supplementary Fig. 1A ). Levels of expression of mRNA encoding the basolateral solute carrier Ntcp were similar in whole liver, freshly isolated hepatocytes, and SCH on day 1, although these were markedly reduced in SCH on days 2-5 ( Supplementary Fig. 1B ).
Canalicular Efflux of CLF and Its Quantification by High Content Cell Imaging
Exposure of SCH, on day 2 after isolation, to CLF resulted in a marked accumulation of fluorescence throughout the cell cytoplasm and there was only very limited substrate efflux into the canalicular regions between adjacent cells (Fig. 2A ). In contrast, marked accumulation of CLF into canalicular regions was evident in SCH from day 3 onwards, and was especially pronounced on days 4 and 5 (Figs. 2B and 2C ), although this was not observed when the cells were exposed to CLF in culture medium which contained EGTA (data not shown). Quantification of canalicular CLF efflux was achieved using the CellomicsArrayscan Spot Detector algorithm. Nuclei were detected following staining with Hoechst 33342 dye (k ex/ em ¼ 365/420 nm), and CLF fluorescence was quantified in a second channel (k em ¼ 530 nm) by detection of canalicular structures as large, irregular regions situated on the boundaries of the cells (Fig. 2D) . The kinetics of canalicular CLF efflux from SCH on day 5 was linear between 5 and 45 min and was non-saturable at substrate concentrations of 1, 5, and 10 mM (Fig. 3) . High signal:noise ratio and good data reproducibility were evident at the 25 min time interval when SCH on day 5 were exposed to 5 mM substrate; therefore, these conditions were selected for subsequent investigations of the effects of drugs on canalicular CLF efflux. The cell imaging approach requires use of Hoechst 33342 to stain nuclei of live cells. When tested at a concentration of 20 mM in membrane vesicle assays, this compound has been reported to exhibit 48% inhibition of OATP1B1, 67% inhibition of OATP1B3, and 13% inhibition of OATP2B1 (Karlgren et al., 2012) . Dose-response curves were not reported and possible effects on other transporters were not assessed. Furthermore, possible inhibition of drug metabolizing enzymes by the Hoechst 33342 has not been explored. In view of the low Hoechst 33342 concentration used in our studies (0.67 mM), we consider that marked effects on transporter function and biotransformation enzyme activities are unlikely but cannot be excluded.
Inhibition of Hepatocyte CLF Efflux by Pharmaceuticals
Concentration-dependent inhibition of canalicular CLF efflux from SCH was observed in the presence of both troglitazone (Figs. 4A-C), which previously has been reported to inhibit biliary transporter activity in vitro and in vivo (Funk et al., 2001a, b; Hirano et al., 2006) , and Dicloxacillin, but not in the presence of the non-inhibitory drug salicylic acid (Kostrubsky et al, 2003) (Fig. 4D) . The inhibition caused by troglitazone was not accompanied by evidence of overt cytotoxicity at the short-time interval using the cell imaging studies, which was assessed by evaluation of cell morphology and by quantification of cellular ATP content and leakage of LDH into the culture medium (data not shown). Quantification of the degree of the inhibition was undertaken by use of the Spot Detector algorithm and doseresponse curves obtained with troglitazone and salicylic acid, and also dicloxacillin are shown in Figure 4D . The IC 50 values observed following addition of these and an additional 42 compounds are listed in Table 2 . The tested compounds comprised 41 pharmaceuticals and 4 non-pharmaceuticals. Each of the 4 non-pharmaceuticals (estradiol 17b-D-glucuronide, a-naphthyl isothiocyanate, Wy-14643, and taurocholate) caused relatively potent inhibition of canalicular CLF efflux (apparent IC 50 <50 mM), as did 15 of the pharmaceuticals. Less potent canalicular CLF efflux inhibition (IC 50 range 66.5-794.4 mM) was observed with 14 of the remaining 26 pharmaceuticals ( Table 2) .
Potencies of Inhibition of SCH Canalicular CLF Efflux Inhibition by Pharmaceuticals Correlated With Potencies of Vesicular Rat Bsep Inhibition
The rat Bsep inhibition and the human MRP2 inhibition data which were used in this analysis were extracted from 2 recent publications ( BARBER ET AL. | 53 respectively) and had been obtained using membranes from transfected insect cells. These values are listed in Table 2 . There was a good overall correlation between the potencies of SCH canalicular CLF efflux inhibition by the 41 tested pharmaceuticals and their rat Bsep inhibition potencies (Fig. 5) . Twelve drugs did not exhibit detectable inhibition of either hepatocyte CLF efflux, or vesicular Bsep inhibition, and 12 drugs exhibited very similar potency values in both assays. However, for 9 drugs (bezafibrate, cloxacillin, dicloxacillin, dexamethasone, fusidic acid, probenecid, rifampicin, rosiglitazone, and troglitazone), their observed potencies of inhibition of SCH CLF efflux were several folds greater than their reported potencies of vesicular Bsep inhibition. Furthermore, 6 drugs (azathioprine, carbamazepine, carmustine, dapsone, gliclazide, and tolbutamide), which inhibited CLF efflux, have been reported not to inhibit vesicular Bsep activity. Two drugs (pioglitazone and rifamycin SV) exhibited less potent inhibition of hepatocyte CLF efflux than of vesicular Bsep activity. A correlation coefficient (r 2 ) of 0.79 was obtained when IC 50 values obtained from the 2 assays were compared for the 23 drugs which exhibited detectable inhibition of both hepatocyte CLF efflux and vesicular Bsep activity.
A comparison between the potencies of SCH CLF efflux inhibition by the drugs and their reported potencies of inhibition of rat Mrp2 was not possible since appropriate rat Mrp2 inhibition data have not been published. Human MRP2 inhibition data were available from the published literature for the drugs and these correlated poorly with the observed potencies of SCH CLF efflux inhibition (Supplementary Fig. 2 ). Only 2 of the drugs (cyclosporin A and rifampicin) have been found to inhibit vesicular MRP2 activity, and in both instances their potencies of vesicular MRP2 inhibition were markedly lower than the corresponding hepatocyte CLF efflux inhibition IC 50 values, while an additional 14 drugs, which exhibited relatively potent inhibition of CLF efflux from SCH have not been found to exhibit detectable inhibition of vesicular human MRP activity.
Potencies of Inhibition of SCH Canalicular CLF Efflux Inhibition Correlated Poorly With Potencies of [ 3 H]-Taurocholate Uptake Inhibition
The sinusoidal entry of CLF into hepatocytes is mediated via basolateral uptake transporters (Mills et al., 1991 (Mills et al., , 1999 . In view of this, it is conceivable that drug-induced inhibition of basolateral hepatocyte transporter activity may have contributed to the observed inhibition of canalicular CLF efflux. Therefore, experiments were undertaken using the probe substrate [ 3 H]-taurocholate to explore whether the drug-induced inhibition of CLF efflux from SCH was accompanied by inhibition of uptake activity. Dose-response curves for the inhibition of [ 3 H]-taurocholate uptake by troglitazone, dicloxacillin, and salicylic acid are shown in Figure 6 . The resulting IC 50 values for these and the other tested compounds are listed in Supplementary Therefore, there was no overall correlation between the 2 parameters (r 2 ¼ 0.071).
Relationship Between Potencies of CLF Inhibition and Peak Plasma Drug Concentrations
The ratios between the reported maximum total plasma concentrations of the drugs in humans (C max ) and their in vitro CLF inhibition IC 50 values were calculated in order to gain preliminary insight into the possible relevance of the in vitro assay data. Nineteen drugs exhibited ratios >0.1 and all of these drugs caused human DILI and in all but one case (probenecid) the reported DILI pattern was cholestatic, or mixed hepatocellular/ cholestatic ( Fig. 8 and Table 2) .
DISCUSSION
Our results demonstrate use of a commercially available high content live cell imaging algorithm to visualize canalicular efflux of the fluorescent substrate, CLF, from SCH and to quantify its inhibition by numerous drugs and other test compounds. The technique exploits the polarized expression of plasma membrane transporters that occurs in SCH, which has been (Dunn et al., 1992; LeCluyse et al., 1994; Li et al., 2009) , and was verified via the immunofluorescence studies undertaken using antibodies that recognized Bsep, Mrp2, and P-gp. When compared with other methods that have been used to evaluate inhibition of bile acid efflux transporter function by drugs in vitro (Dawson et al., 2012; Graf and Boyer, 1990; Hirano et al., 2006; Lerche-Langrand and Toutain, 2000; Mills et al., 1999; Orsler et al., 1999; Oude Elferink et al., 1990; Pederson et al., 2013; Smith et al., 1985; Studenberg and Brouwer 1993) , CLF imaging has several notable advantages. It involves direct live cell analysis of biliary excretion in a physiologically relevant cell system, yields highly sensitive and reproducible data that exhibit an excellent dynamic range and does not require the use of radiolabeled substrates. Since cell viability can be assessed on the same sample wells used for imaging analysis, it is possible to demonstrate directly that any observed effects of test compounds on canalicular efflux are not indirectly due to overt cell cytotoxicity. An inherent limitation of all transport studies undertaken using SCH is that any observed inhibition of apical efflux may arise as a secondary consequence of inhibition of sinusoidal substrate uptake into the cells, as well as via direct apical efflux inhibition. Therefore, inhibition of CLF uptake into hepatocytes by drugs could result in inhibition of canalicular excretion. We were unable to assess directly the effects of drugs on sinusoidal CLF uptake into hepatocytes because the intensity of fluorescence effluxed into sealed canalicular pockets far exceeded hepatocellular fluorescence; therefore, the latter could not be quantified. Consequently, we assessed whether the test compounds used in our studies affected sinusoidal transporter function by exploring their effects on SCH uptake of the [ 3 H]-taurocholate, which is mediated primarily by Ntcp (Muller and Jansen, 1997) . Although some drugs that we found to exhibit potent inhibition of canalicular CLF efflux also inhibited [ 3 H]-taurocholate uptake into SCH, numerous other drugs did not, and overall there was a poor correlation between inhibition of the 2 transporter functions. However, these data do not address possible inhibition of organic transport proteins which also play an important role in cellular uptake of CLF (de Waart et al., 2010) . CLF was chosen as a probe substrate because it is a fluorescent bile salt analogue that has been used to explore biliary 56 | TOXICOLOGICAL SCIENCES, 2015, Vol. 148, No. 1 excretion in vitro and in vivo, and has been shown to exhibit kinetics of sinusoidal uptake and apical efflux in rat hepatocytes that are similar to those of the bile salts cholylglycine and glycolithocholate (Mills et al., 1991) . Furthermore, similar biliary excretion rates were determined for CLF in vivo in normal rats, and in TR-rats, which are deficient in Mrp2 activity, and in vitro in hepatocytes from normal and TR-rats (Mills et al., 1999) . In view of this, it was inferred that CLF was likely to be a substrate of the apical bile salt transporter of hepatocytes (ie, Bsep) and not of Mrp2. In contrast, subsequent studies undertaken using membranes prepared from insect cells transfected with MRP2 or BSEP revealed that, in this assay system, CLF was transported by vesicles which expressed MRP2 but not by vesicles which expressed BSEP (de Waart et al., 2010) . Furthermore, a marked reduction in biliary excretion of CLF was evident in mice lacking Mrp2, when compared with wild type mice (de Waart et al., 2010) . Therefore, the most likely explanation for the good overall correlation between potencies of inhibition of hepatocellular CLF efflux and inhibition of vesicular Bsep activity by many pharmaceuticals (Table 2 and Fig. 5A ) is that many drugs exhibit similar potencies of inhibition of Bsep and Mrp2 activity. Although we observed a poor correlation between potencies of SCH CLF efflux inhibition by the drugs and published human MRP2 inhibition data, a species difference between human MRP2 and rat Mrp2 inhibition is conceivable. A more appropriate comparison would have been between CLF efflux inhibition and rat Mrp2 inhibition. We could not undertake this analysis due to the very limited amount of information available in the published scientific literature on rat Mrp2 inhibition by drugs. This is an important data gap. It is conceivable, although unlikely, that the biliary transporter specificity of CLF in intact hepatocytes might differ markedly from that observed when Bsep is expressed in transfected insect cells. We consider that our data highlight a need to evaluate directly whether drugs that inhibit BSEP/Bsep also inhibit MRP2/Mrp2. This could be a synergistic DILI risk factor, by causing accumulation of drugs and/or drug metabolites in hepatocytes. An example of a drug that exhibits potent inhibition both of BSEP and MRP2 activity is troglitazone (Chang et al., 2013; Funk et al., 2001a) . Whereas many drugs exhibited IC 50 values for CLF inhibition that were equivalent to their reported vesicular BSEP inhibition IC 50 values, in some instances the CLF inhibition values were markedly lower, eg, troglitazone. Troglitazone is converted to a sulfated metabolite that is a markedly more potent Bsep inhibitor than troglitazone itself (Funk et al., 2001a; Masubuchi, 2006) . Although it is possible that this drug is biotransformed to its sulfated metabolite in the SCH, this is considered unlikely to have occurred to a significant extent during the 25-min incubation period used in the CLF efflux studies. The other drugs for which apparent IC 50 values for inhibition of canalicular CLF efflux were markedly lower than the corresponding vesicular Bsep inhibition IC 50 values were azothiaprine, bezafibrate, cloxacillin, dicloxacillin, and probenecid. A positive relationship has been reported between elevated plasma concentrations of the 6-methylmercaptopurine ribonucleotide metabolite of azathioprine, and abnormal human liver function tests (Cuffari et al., 1996; Dubinsky et al., 2002) . Metabolite profiling was not undertaken in our studies and should be assessed in the future.
Since our studies were undertaken using rat hepatocytes, it is inappropriate to infer that our data are directly relevant to DILI in humans. Nevertheless, we calculated the ratios between the reported maximum concentrations of the tested drugs in human plasma (C max ), and their in vitro CLF efflux IC 50 values in order to gain preliminary insight into the potential in vivo significance of SCH CLF efflux inhibition. This approach is based on that used to interpret the risk of drug-drug interactions in vivo posed by transporter inhibition (FDA, 2012) , and has been used previously by Morgan et al. (2013) to aid interpretation of in vitro BSEP inhibition data. The resulting data plot (Fig. 8) suggests that, if the potencies of inhibition of rat CLF apical efflux can be reproduced using human hepatocytes, many of the tested drugs could have the potential to inhibit biliary transporter function in vivo. Moreover, all of the drugs that exhibited C max /IC 50 ratios that exceeded 0.1 have been reported to cause DILI in humans (Fig. 8) . This observation is consistent with the hypothesis that biliary transport inhibition is a human DILI risk factor and suggests that use of the technique that we have described has the potential to aid in investigation of the role played by biliary transport inhibition in liver injury caused by drugs. To explore this opportunity further, it will be important to undertake studies using our cell imaging approach in human hepatocytes.
Our data analysis also highlights the importance of considering in vivo drug exposure when attempting to interpret in vitro transporter inhibition data. For example, although ibuprofen and ciprofibrate exhibited relatively non-potent inhibition of canalicular CLF efflux (IC 50 values were 290 and 384 mM, respectively), calculation of their C max /IC 50 ratios indicated that these effects are likely to be relevant in vivo due to the high plasma concentrations of the drugs. In contrast, the more potent CLF efflux inhibition exhibited by dexamethasone (67 mM) is unlikely to be relevant due to low in vivo exposure to this drug.
Biliary transport inhibition is one of several mechanisms by which liver injury may be initiated by drugs. Other important mechanisms include mitochondrial injury, formation of chemically reactive metabolites, potent cell cytotoxicity, and immune activation (Abboud and Kaplowitz, 2007; Greer et al., 2010; Thompson et al., 2011) . Published data have implicated some or all of these additional mechanisms in DILI caused by many of the drugs that we tested (eg, Gustafsson et al., 2014; Kenna et al., 2015; Ohbuchi et al., 2009; Rodriguez and Acosta Jr., 1997; Tettey et al., 2001; Thompson et al., 2012) . Therefore, it is important to interpret data from biliary transporter inhibition studies alongside data which address other potential DILI initiating mechanisms when interpreting their potential adverse functional consequences, as we have proposed elsewhere (Kenna et al., 2015; Thompson et al., 2012) .
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